Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Depreciation & Amortization (CF) (2019 - 2025)

Keros Therapeutics' Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $400000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 20.48% year-over-year to $400000.0; the TTM value through Dec 2025 reached $1.5 million, up 22.78%, while the annual FY2025 figure was $1.5 million, 22.78% up from the prior year.
  • Depreciation & Amortization (CF) reached $400000.0 in Q4 2025 per KROS's latest filing, up from $395000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $400000.0 in Q4 2025 to a low of $80000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $230250.0, with a median of $228500.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 238.46% in 2022, then tumbled 37.99% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $104000.0 in 2021, then grew by 22.12% to $127000.0 in 2022, then surged by 94.49% to $247000.0 in 2023, then skyrocketed by 34.41% to $332000.0 in 2024, then rose by 20.48% to $400000.0 in 2025.
  • Per Business Quant, the three most recent readings for KROS's Depreciation & Amortization (CF) are $400000.0 (Q4 2025), $395000.0 (Q3 2025), and $370000.0 (Q2 2025).